首页> 外文OA文献 >Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial

【2h】

Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial

机译：Lasofoxifene和绝经后骨质疏松妇女的心血管事件：Lasofoxifene（PEARL）绝经后评估和降低风险的五年结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ensrud, K; Lacroix, A; Thompson, JR; Thompson, DD; Eastell, R; Reid, DM; Vukicevic, S; Cauley, J; Barrett-Connor, E; Armstrong, R; Welty, F; Cummings, S;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. [J] . Ensrud K, LaCroix A, Thompson JR, Circulation: An Official Journal of the American Heart Association . 2010,第17期

机译：Lasofoxifene和绝经后骨质疏松妇女的心血管事件：Lasofoxifene（PEARL）试验的绝经后评估和降低风险的五年结果。
2. The PEARL trial: lasofoxifene and incidence of fractures,breast cancer and cardiovascular events in postmenopausal osteoporotic women [J] . Slobodan Vukicevic International journal of clinical rheumatology. . 2011,第4期

机译：PEARL试验：拉莫昔芬与绝经后骨质疏松妇女的骨折，乳腺癌和心血管事件发生率
3. Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of Lasofoxifene in postmenopausal women with osteoporosis 2010;362:686-96. [J] . Reginster JY Expert opinion on pharmacotherapy . 2010,第10期

机译：拉索昔芬在骨质疏松症治疗中的兴趣。 Lasofoxifene对绝经后骨质疏松妇女的评估2010; 362：686-96。
4. Soy Isoflavone Supplementation May Reduce the Risks of Hypertension and Osteoporosis in Postmenopausal Women [C] . William W. Wong, Paula Amato, Ronald L. Young, . 2002

机译：补充大豆异黄酮可降低绝经后妇女高血压和骨质疏松症的风险
5. An assessment of risk factors and attitude toward physical activity in postmenopausal women committed to an osteoporosis related research project. [D] . Hammond, Judy Oliver. 1991

机译：致力于骨质疏松症相关研究项目的绝经后妇女的危险因素和对体育活动态度的评估。
6. RANKL Inhibition With Denosumab Does Not Influence 3-year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk [O] . Elizabeth J. Samelson, Paul D. Miller, Claus Christiansen, -1

机译：地诺单抗对RANKL的抑制作用不会影响绝经后骨质疏松和高心血管风险女性的主动脉钙化或心血管不良事件发生率的3年进程
7. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial [O] . Ensrud, K, Lacroix, A, Thompson, JR, 2010

机译：Lasofoxifene和绝经后骨质疏松妇女的心血管事件：Lasofoxifene（PEARL）绝经后评估和降低风险的五年结果
8. Risk Factors for Osteoporosis and Oral Bone Loss in Postmenopausal Women. [R] . Wactawski-Wende, J. 2001

机译：绝经后妇女骨质疏松症和口腔骨丢失的危险因素。

Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial

著录项

引文网络

相似文献

相关主题

期刊订阅